Loss of Cyp8b1 improves glucose homeostasis by increasing GLP-1

by Kaur A., Patankar J.V., de Haan W., Ruddle P., Wijesekara N., Groen A.K., Verchere C.B., Singaraja R.R, Hayden M.R.
Published 2015

Huntingtin interacting proteins 14 and 14-like are required for chorioallantoic fusion during early placental development

by Sanders S.S., Hou J., Sutton L.M., Garside V.C., Mui K.K.N., Roshni Rebecca Singaraja, Hayden M.R., Hoodless P.A.
Published 2016

Low levels of human HIP14 are sufficient to rescue neuropathological, behavioural, and enzymatic defects due to loss of murine HIP14 in Hip14-/- mice

by Young F.B., Franciosi S., Spreeuw A., Deng Y., Sanders S., Tam N.C.M., Huang K., Singaraja R.R., Zhang W., Bissada N., Kay C., Hayden M.R.
Published 2018

Segregation of LIPG, CETP, and GALNT2 mutations in Caucasian families with extremely high HDL cholesterol

by Tietjen I., Hovingh G.K., Singaraja R.R., Radomski C., Barhdadi A., McEwen J., Chan E., Mattice M., Legendre A., Franchini P.L., Dubé M.-P., Kastelein J.J.P., Hayden M.R.
Published 2018

Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse

by Kusko R., Dreymann J., Ross J., Cha Y., Escalante-Chong R., Garcia-Miralles M., Tan L.J., Burczynski M.E., Zeskind B., Laifenfeld D., Pouladi M., Geva M., Grossman I., Hayden M.R.
Published 2019

Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease

by Southwell A.L., Franciosi S., Villanueva E.B., Xie Y., Winter L.A., Veeraraghavan J., Jonason A., Felczak B., Zhang W., Kovalik V., Waltl S., Hall G., Pouladi M.A., Smith E.S., Bowers W.J., Zauderer M., Hayden M.R.
Published 2016

Partial rescue of some features of Huntington Disease in the genetic absence of caspase-6 in YAC128 mice

by Wong B.K.Y., Ehrnhoefer D.E., Graham R.K., Martin D.D.O., Ladha S., Uribe V., Stanek L.M., Franciosi S., Qiu X., Deng Y., Kovalik V., Zhang W., Pouladi M.A., Shihabuddin L.S., Hayden M.R.
Published 2016

Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes

by Maillet, A, Tan, K, Chai, X, Sadananda, S.N, Mehta, A, Ooi, J, Hayden, M.R, Pouladi, M.A, Ghosh, S, Shim, W, Brunham, L.R
Published 2020

pS421 huntingtin modulates mitochondrial phenotypes and confers neuroprotection in an HD hiPSC model

by Xu, X., Ng, B., Sim, B., Radulescu, C.I., Yusof, N.A.B.M., Goh, W.I., Lin, S., Lim, J.S.Y., Cha, Y., Kusko, R., Kay, C., Ratovitski, T., Ross, C., Hayden, M.R., Wright, G., Pouladi, M.A.
Published 2021

Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease

by Garcia-Miralles, M, Hong, X, Tan, L.J, Caron, N.S, Huang, Y, To, X.V, Lin, R.Y, Franciosi, S, Papapetropoulos, S, Hayardeny, L, Hayden, M.R, Chuang, K.-H, Pouladi, M.A
Published 2020

Accurate prediction of the functional significance of single nucleotide polymorphisms and mutations in the ABCA1 gene

by Brunham L.R., Singaraja R.R., Pape T.D., Kejariwal A., Thomas P.D., Hayden M.R.
Published 2019

CAG size-specific risk estimates for intermediate allele repeat instability in Huntington disease

by Semaka, A., Kay, C., Doty, C., Collins, J.A., Bijlsma, E.K., Richards, F., Goldberg, Y.P., Hayden, M.R.
Published 2013

Inhibition of Excessive Monoamine Oxidase A/B Activity Protects Against Stress-induced Neuronal Death in Huntington Disease

by Ooi, J, Hayden, M.R, Pouladi, M.A
Published 2020

Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin

by Brunham, L.R., Lansberg, P.J., Zhang, L., Miao, F., Carter, C., Hovingh, G.K., Visscher, H., Jukema, J.W., Stalenhoef, A.F., Ross, C.J.D., Carleton, B.C., Kastelein, J.J.P., Hayden, M.R.
Published 2012

A new mutation for Huntington disease following maternal transmission of an intermediate allele

by Semaka, A., Kay, C., Belfroid, R.D.M., Bijlsma, E.K., Losekoot, M., Langen, I.M. van, Maarle, M.C. van, Oosterloo, M., Hayden, M.R., Belzen, M.J. van
Published 2015

Frequency of the loss of CAA interruption in theHTTCAG tract and implications for Huntington disease in the reduced penetrance range

by Black, H.F., Wright, G.E.B., Collins, J.A., Caron, N., Kay, C., Xia, Q.W., Arning, L., Bijlsma, E.K., Squitieri, F., Nguyen, H.P., Hayden, M.R.
Published 2020

Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease

by Miniarikova, J., Zanella, I., Huseinovic, A., Zon, T. van der, Hanemaaijer, E., Martier, R., Koornneef, A., Southwell, A.L., Hayden, M.R., Deventer, S.J. van, Petry, H., Konstantinova, P.
Published 2016

Length of Uninterrupted CAG, Independent of Polyglutamine Size, Results in Increased Somatic Instability, Hastening Onset of Huntington Disease

by Wright, G.E.B., Collins, J.A., Kay, C., McDonald, C., Dolzhenko, E., Xia, Q.W., Becanovic, K., Drogemoller, B.I., Semaka, A., Nguyen, C.M., Trost, B., Richards, F., Bijlsma, E.K., Squitieri, F., Ross, C.J.D., Scherer, S.W., Eberle, M.A., Yuen, R.K.C., Hayden, M.R.
Published 2019